Metformin: new data for an old molecule
Abstract
Metformin is the first-line oral agent for the treatment of type 2 diabetes according to the guidelines. Metformin decreases hepatic glucose production, does not induce weight gain and does not increase the risk of hypoglycemia. However, decades after its introduction, its mode of action has been only recently highlighted. The side effects of metformin are well known and consist primarily of digestive problems. Although rare, the dreaded complication is lactic acidosis, which can develop in patients with severe renal insufficiency or in conditions of low perfusion. The purpose of this article is to review the indications, risks and benefits of this drug, but also to discuss new evidence related to its mechanism of action and the conditions that increase the risk of lactic acidosis.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.